Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454945 | 0.80 | CA2 (0.63) | PSIP1HSD11B1SMN1; SMN2TSHRMAPT | |
| SCHEMBL777601 | 0.78 | PSIP1 (0.67) | PSIP1HSD11B1SMN1; SMN2TSHRMAPT | |
| SCHEMBL64761 | 0.78 | PSIP1 (0.67) | PSIP1HSD11B1SMN1; SMN2TSHRMAPT | |
| SCHEMBL1001018 | 0.77 | HSD11B1 (0.69) | PSIP1HSD11B1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7207184 | 0.77 | CA2 (0.66) | PSIP1HSD11B1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL3329009 | 0.76 | PSIP1 (0.64) | PSIP1HSD11B1SMN1; SMN2TSHRMAPT | |
| SCHEMBL180713 | 0.76 | PSIP1 (1.00) | PSIP1HSD11B1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL5013934 | 0.75 | PSIP1 (0.56) | PSIP1HSD11B1SMN1; SMN2TSHRMAPT | |
| SCHEMBL8630142 | 0.75 | NPC1 (0.43) | PSIP1SMN1; SMN2NPC1LMNAKMT2A | |
| SCHEMBL270706 | 0.75 | MMP2 (0.77) | PSIP1HSD11B1SMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| EP-0454121-B1 | Azatetracyclic compounds | SEARLE & CO (US) | 1996-11-13 | — | — | EP | claimed |
| US-5250391-A | Photopolymer composition and its use | HUGHES AIRCRAFT COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| US-5223613-A | Prepared from cyclopenta(c)pyrrole derivatives; drug intermediates; antiemetics, anixiolytics | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | claimed |
| US-5106718-A | Heat resistant relief structures | CIBA-GEIGY CORPORATION (US) | 1992-04-21 | — | — | US | claimed |
| EP-0454121-A2 | Azatetracyclic compounds | G.D. Searle & Co. (US) | 1991-10-30 | — | — | EP | claimed |
| EP-0364949-A2 | Heat-stable positive photoresist | CIBA-GEIGY AG (CH) | 1990-04-25 | — | — | EP | claimed |
| EP-0337229-A2 | Substituted pyri(mi)dines | BAYER AG (DE) | 1989-10-18 | — | — | EP | claimed |
| US-4841030-A | Azo reactive dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | claimed |
| US-4054480-A | AS A CATALYST, ACRYLIC POLYMERS | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1977-10-18 | — | — | US | claimed |
| US-4053373-A | ELECTROPLATING OF NICKEL, COBALT, NICKEL-COBALT, NICKEL-IRON, COBALT-IRON AND NICKEL-IRON-COBALT DEPOSITS | M & T CHEMICALS INC. (US) | 1977-10-11 | — | — | US | claimed |
| EP-2177519-B1 | TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT | NIPPON SODA CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-9029552-B2 | Tetrazoyloxime derivative and plant disease control agent | NIPPON SODA CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-4024166-A | Process for the preparation of 13β-alkyl-4-gonene-3,17-diones | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
| US-4017545-A | Process for the preparation of bicycloalkane derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-04-12 | — | — | US | disclosed |
| US-4008253-A | Bicycloalkanes | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | PSIP1 2534/4885HSD11B1 1752/4885SMN1; SMN2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.